New pill targets rare gene fault in advanced cancers
NCT ID NCT04683250
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called TAS0953/HM06 in people with advanced solid tumors that have specific RET gene abnormalities. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well the drug shrinks tumors. About 244 adults with RET-altered non-small cell lung cancer or other solid tumors will take the drug orally twice a day in 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAS0953/HM06 (a targeted drug that blocks the RET protein to slow or stop cancer growth)
What this could lead to
If successful, this could provide a new treatment option for people with advanced cancers that have specific RET gene changes, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. Results may not apply to all patients with RET alterations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RET-ALTERED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chao Family Comprehensive Cancer Center
TERMINATEDOrange, California, 92868-3298, United States
-
Henry Ford Hospital
TERMINATEDDetroit, Michigan, 48202, United States
-
Kanagawa Cancer Center
RECRUITINGKanagawa, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kansai Medical University Hospital
RECRUITINGHirakata-shi, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kurashiki Central Hospital
RECRUITINGOkayama, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
TERMINATEDNew York, New York, 10016, United States
-
Massachusetts General Hospital
TERMINATEDBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
TERMINATEDNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Hospital Organization Kyushu Cancer Center
RECRUITINGFukuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Okayama University Hospital
RECRUITINGOkayama, Okayama-ken, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest - Cancer & Hematology Centers of Western Michigan
TERMINATEDGrand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shizuoka Cancer Center
RECRUITINGShizuoka, Shizuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Center
TERMINATEDStanford, California, 94305-5826, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sarah Cannon Research Institute/Tennessee Oncology
TERMINATEDNashville, Tennessee, 37203, United States
-
The University of Texas M. D. Anderson Cancer Center
TERMINATEDHouston, Texas, 77030-4009, United States
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••